Considerations for Developing Biopharmaceuticals: FDA Perspective

Modern Biopharmaceuticals: Design, Development and Optimization

Volumn 4, Issue , 2008, Pages 1637-1667

  Brorson, Kurt ^a   Swann, Patrick G ^a   Brown, Janice ^a   Wilcox, Barbara ^a   Shapiro, Marjorie A ^a  

^a Center for Drug Evaluation and Research   (United States)

Author keywords

Bioburden; Encephalopathy; Feasibility trials; Heterohybridoma; Specter

Indexed keywords

EID: 57749086529     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527620982.ch68     Document Type: Chapter

References (84)

1. Manual of Policies and Procedures. Review Management: Priority Review Policy; MAPP 6020.3. Center for Drug Evaluation and Research, Food and Drug Administration: Rockville MD, 1996.
2. Manual of standard operating procedures and policies. Regulatory- License applications complete review and issuance of action letters. SOPP 8405. Center for Biologics Evaluation and Research, Food and Drug Administration: Rockville MD, 2003.
3. Guidance for Industry. Standards for the prompt review of efficacy supplements, including priority efficacy supplements. Food and Drug Administration: Rockville MD, 1998.
4. Guidance for Industry; Content and Format of Investigational New Drug Applications (INDs) References 1663 for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products. Food and Drug Administration: Rockville MD, 1996.
5. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. Food and Drug Administration: Rockville MD, 1997.
6. Text on validation of analytical procedures, Q2A. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Geneva Switzerland, 1994.
7. Validation of analytical procedures: methodology, Q2B. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Geneva Switzerland, 1996.
8. Guidance on Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin, Q5A. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Geneva Switzerland, 1998.
9. Final Guideline on Quality of Biotechnical Products: Analysis of the Expression Construct in Cells Used for the Production of r-DNA Derived Protein Products, Q5B. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Geneva Switzerland, 1996.
10. Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products, Q5C. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Geneva Switzerland, 1995.
11. Guidance on Quality of Biotechnological/Biological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/ Biological Products, Q5D. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Geneva Switzerland, 1998.
12. Guidance on Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, Q6B. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Geneva Switzerland, 1999.
13. Guidance on Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals, S6. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Geneva Switzerland, 1997.
14. FDA Guidance Document Concerning Use of Pilot Manufacturing Facilities for the Development and Manufacturing of Biological Products. Docket No. 95D-0131; Food and Drug Administration: Rockville MD, 1995.
15. Good manufacturing practice guidance for active pharmaceutical ingredients, Q7A. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Geneva Switzerland, 2000.
16. Guidance for Industry - Changes to an Approved Application: for Specified Biotechnology and Specified Synthetic Biological Products. Food and Drug Administration: Rockville MD, 1997.
17. Guidance for Industry FDA Guidance for Human Somatic Cell Therapy and Gene Therapy. Food and Drug Administration: Rockville MD, 1998.
18. Draft Guidance for Industry: Drugs, Biologics, and Medical Devices Derived from Bioengineered Plants for Use in Humans and Animals. Food and Drug Administration: Rockville MD, 2002.
19. Point to Consider in the Manufacture and Testing of Therapeutic Products for Human Use Derived From Transgenic Animals. Food and Drug Administration: Rockville MD, 1995.
20. Fischer, R., Stoger, E., Schillberg, S., Christou, P., Twyman, R. M., Plant-based production of biopharmaceuticals. Curr Opin Plant Biol 2004, 7(2), 152-158.
21. Rudolph, NS., Biopharmaceutical production in transgenic livestock. Trends Biotechnol 1999, 17, (9), 367-374.
22. Knäblein, J., Biotech: A New Era In The New Millennium ? Fermentation and Expression of Biopharmaceuticals in Plants. SCREENING -Trends Drug Disc 2003, 4, 14-16.
23. Knäblein, J., McCaman, M., Modern Biopharmaceuticals-Recombinant Protein Expression in Transgenic Plants. SCREENING - Trends Drug Disc 2003, 6, 33-35.
24. Chu, L., Robinson, D., Industrial choices for protein production by large-scale cell culture. Curr Opin Biotechnol 2001, 12, 180-187.
25. Kretzmer, G., Industrial processes with animal cells. Appl Microbiol Biotechnol 2002, 59(2-3), 135-142.
26. Fahrner, R., Whitney, D., Vanderlaan, M., Blank, GS., Performance comparison of protein A affinity-chromatography sorbents for purifying recombinant monoclonal antibodies. Biotechnol Appl Biochem 1999, 30, 121-128.
27. Fuglistaller, P., Comparison of immunoglobulin binding capacities and ligand leakage using eight different protein A affinity chromatography matrices. J Immunol Methods 1989, 124, 171-177.
28. Godfrey, M., Kwasowski, P., Clift, R., Marks, V., Assessment of the suitability of commercially available SpA affinity solid phases for the purification of murine monoclonal antibodies at process scale. J Immunol Methods 1993, 160, 97-105.
29. Hahn, R., Schlegel, R., Jungbauer, A., Comparison of protein A affinity sorbents. J Chromatogr B 2003, 790, 35-51.
30. Endres, H.N., Johnson, J. A., Ross, C. A., Welp, J. K., Etzel, M.R., Evaluation of an ionexchange membrane for the purification of plasmid DNA. Biotechnol Appl Biochem 2003, 37 (Pt 3), 259-266.
31. Anspach, F. B., Curbelo, D., Hartmann, R., Garke, G., Deckwer, W. D., Expanded-bed chromatography in primary protein purification. J Chromatogr A 1999, 865(1-2), 129-144.
32. Guidance for Industry. Drug Product. Chemistry, Manufacturing and Controls Information. Food and Drug Administration: Rockville MD, 2003.
33. Draft Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice. Food and Drug Administration: Rockville MD, 2004.
34. Guidance for industry for the submission of chemistry, manufacturing and controls information for a therapeutic recombinant DNA-derived product or a monoclonal antibody product for in vivo use. Food and Drug Administration: Rockville MD, 1996.
35. The common technical document for the registration of pharmaceuticals for human use: Quality Module 3, M4Q. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Geneva Switzerland, 2003.
36. PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. Food and Drug Administration: Rockville MD, 2004.
37. Xu, Y., Brorson, K., An overview of quantitative PCR assays for biologicals: quality and safety evaluation. Dev Biol (Basel) 2003, 113, 89-98.
38. Guideline on validation of the Limulus Amebocyte test as an end-product endotoxin test for human and animal parenteral drugs, biological products and medical devices. Food and Drug Administration: Rockville MD, 1987.
39. Griffiths, E., WHO Expert Committee on Biological Standardization Highlights of the Meeting of October 1996. Biologicals 1997, 25, 359-362.
40. Final Guidance on Stability Testing of Biotechnological/ Biological Products, Q5C. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Geneva Switzerland, 1996.
41. Guidance Concerning Demonstration of Comparability of Human Biological Products. Food and Drug Administration: Rockville MD, 2002.
42. Guidance for Industry: Analytical Procedures and Methods Validation Chemistry, Manufacturing, and Controls Documentation. Food and Drug Administration: Rockville MD, 2000.
43. Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit: 1996.
44. Brorson, K., Norling, L., Hamilton, E., Lute, S., Lee, K., Curtis, S., Xu, Y., Current and future approaches to ensure the viral safety of biopharmaceuticals. Dev Biol (Basel) 2004, 118, 17-29.
45. Jones, D., Kroos, N., Anema, R., van Montfoort, B., Vooys, A., van der Kraats, S., van der Helm, E., Smits, S., Schouten, J., Brouwer, K., Lagerwerf, F., van Berkel, P., Opstelten, D.J., Logtenberg, T., Bout, A., High-level expression of recombinant IgG in the human cell line per.c6. Biotechnol Prog 2003, 19, 163-168.
46. Guidance for Industry. Drug Substance. Chemistry, Manufacturing and Controls Information. Food and Drug Administration: Rockville MD, 2004.
47. Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease vCJD) by Blood and Blood Products. Food and Drug Administration: Rockville MD, 2002.
48. Guideline on general principles of process validation. Food and Drug Administration: Rockville MD, 1987.
49. Elimination of establishment license application for specified biotechnology and synthetic biological products. Federal Register 1996, 61(94), 24227-24233.
50. Reichert, J. M., Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov 2003, 2(9), 695-702.
51. Reichert, J. M., Therapeutic monoclonal antibodies: trends in development and approval in the US. Curr Opin Mol Ther 2002, 4(2), 110-118.
52. Reichert, J. M., Monoclonal antibodies in the clinic. Nat Biotechnol 2001, 19(9), 819-822.
53. Stein, K. E., Overcoming obstacles to monoclonal antibody product development and approval. Trends Biotechnol 1997, 15(3), 88-90.
54. Glennie, M.J., Johnson, P.W., Clinical trials of antibody therapy. Immunol Today 2000, 21(8), 403-410.
55. Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J. J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., Varet, B., Mayeux, P., Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002, 346, 469-475.
56. Clark, M., Antibody humanization: a case of the 'Emperor's new clothes'? Immunol Today 2000, 21(8), 397-402.
57. Safety Studies for Biotechnological Products. Food and Drug Administration: Rockville MD, 1997.
58. Serabian, M.A., Pilaro, A. M., Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond. Toxicol Pathol 1999, 27(1), 27-31.
59. Haznedaroglu, I. C., Goker, H., Turgut, M., Buyukasik, Y., Benekli, M., Thrombopoietin as a drug: biologic expectations, clinical realities, and future directions. Clin Appl Thromb Hemost 2002, 8(3), 193-212.
60. Verhelst, D., Rossert, J., Casadevall, N., Kruger, A., Eckardt, K.-U., Macdougall, I., Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 2004, 363, 1768-1771.
61. Hermeling, S., Crommelin, D. J., Schellekens, H., Jiskoot, W., Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 2004, 21(6), 897-903.
62. Schellekens, H., Casadevall, N., Immunogenicity of biopharmaceuticals. The European perspective. Dev Biol (Basel) 2003, 112, 23-28.
63. Schellekens, H., Crommelin, D.J., Equivocal role of micelles in Eprex adverse events. Nat Biotechnol 2003, 21(11), 1265; author reply 1266.
64. Macdougall, I. C., Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another. Curr Med Res Opin 2004, 20(1), 83-86.
65. Collins, A. J., Li, S., Adamson, J.W., Gilbertson, D.T., Assessment of pure red cell aplasia in US dialysis patients: the limits of the Medicare data. Am J Kidney Dis 2004, 43(3), 464-470.
66. Hermeling, S., Schellekens, H., Crommelin, D.J., Jiskoot, W., Micelle-associated protein in epoetin formulations: A risk factor for immunogenicity? Pharm Res 2003, 20(12), 1903-1907.
67. Bennett, C., Luminari, S., Nissenson, A., Tallman, M., Klinge, S., McWilliams, N., McKoy, J., Kim, B., Lyons, E., Trifilio, S., Raisch, D., Evens, A., Kuzel, T., Schumock, G., Belknap, S., Locatelli, F., Rossert, J., Casadevall, N., Pure Red-Cell Aplasia and Epoetin Therapy. N Engl J Med 2004, 351, 1403-1408.
68. Locatelli, F., Aljama, P., Barany, P., Canaud, B., Carrera, F., Eckardt, K., Macdougall, I., Macleod, A., Ho, W., Wiecek, A., Cameron, S., Erythropoiesis-stimulating agents and antibody- mediated pure red-cell aplasia: where are we now and where do we go from here? Nephrol Dial Transplant 2004, 19, 288-293.
69. Sharma, B., Bader, F., Templeman, T., Lisi, P., Ryan, M., Haeavner, G., Technical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with Eprex. Industry Science (Eur. Assoc. Hospital Pharmacists) 2004, 5, 86-91.
70. Miller, K. J., Bowsher, R. R., Celniker, A., Gibbons, J., Gupta, S., Lee, J.W., Swanson, S. J., Smith, W. C., Weiner, R. S., Workshop on bioanalytical methods validation for macromolecules: summary report. Pharm Res 2001, 18(9), 1373-1383.
71. Mire-Sluis, A., Barrett, Y., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., Swanson, S., Taniguchi, G., Wierda, D., Zuckerman, L., Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004, 289, 1-16.
72. Swanson, S. J., Ferbas, J., Mayeux, P., Casadevall, N., Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract 2004, 96(3), c88-c95.
73. Bussiere, J. L., Animal models as indicators of immunogenicity of therapeutic proteins in humans. Dev Biol (Basel) 2003, 112, 135-139.
74. Klingbeil, C., Hsu, D.H., Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use. Toxicol Pathol 1999, 27(1), 1-3.
75. Trowsdale, J., Parham, P., Mini-review: defense strategies and immunity-related genes. Eur J Immunol 2004, 34(1), 7-17.
76. Treacy, G., Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody. Hum Exp Toxicol 2000, 19(4), 226-228.
77. Bugelski, P. J., Herzyk, D.J., Rehm, S., Harmsen, A. G., Gore, E.V., Williams, D.M., Maleeff, B. E., Badger, A. M., Truneh, A., O'Brien, S. R., Macia, R. A., Wier, P. J., Morgan, D. G., Hart, T. K., Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Hum Exp Toxicol 2000, 19(4), 230-243.
78. Garnick, R. L., Raw materials as a source of contamination in large-scale cell culture. Dev Biol Stand 1998, 93, 21-29.
79. Garnick, R. L., Experience with viral contamination in cell culture. Dev Biol Stand 1996, 88, 49-56.
80. Guidance for Industry: Part 11, Electronic Records; Electronic Signatures - Scope and Application. Food and Drug Administration: Rockville MD, 2003.
81. Draft Guidance for Industry: Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP. Food and Drug Administration: Rockville MD, 2004.
82. Pharmaceutical cGMPs for the 21st century - a risk based approach. Final report. Food and Drug Administration: Rockville MD, 2004.
83. New Drug and Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible. Food and Drug Administration: Rockville MD, 2002.
84. Gilbert, J., Henske, P., Singh, A. Rebuilding Big Pharma's Business Model. Windhover Information: November, 2003.